Home › Funds › Caligan Partners LP › LBRX
Caligan Partners LP position in LBRX
LB PHARMACEUTICALS INC · Health Care
Caligan Partners LP reported holding 1,438,070 shares of LBRX (LB PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$46.7M, representing 2.73% of its reported portfolio and ranking #9 among its reported holdings. Caligan Partners LP has disclosed LBRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's LBRX position evolved
Caligan Partners LP first disclosed a stake in LBRX in Q1 2026 at 1,438,070 shares (US$34.6M). The position peaked in Q2 2026 at 1,438,070 shares, worth US$46.7M. Across 2 filings, Caligan Partners LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 1,438,070 shares valued at US$46.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.44M | $34.63M | New |
| Q2 2026 | 1.44M | $46.67M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LBRX and 13F data
LBRX (LB PHARMACEUTICALS INC) is a Health Care company. 110 other funds we track also report a position in LBRX — the largest reported positions include Deep Track Capital, LP (US$108.8M), RA CAPITAL MANAGEMENT, L.P. (US$71.7M), Trails Edge Capital Partners, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LBRX
- Deep Track Capital, LP 3.35M sh · $108.82M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.21M sh · $71.68M · Q2 2026
- Trails Edge Capital Partners, LP 1.52M sh · $49.43M · Q2 2026
- Commodore Capital LP 1.50M sh · $48.68M · Q2 2026
- TCG Crossover Management, LLC 1.45M sh · $46.97M · Q2 2026
- Spruce Street Capital LP 1.38M sh · $44.66M · Q2 2026
- Nantahala Capital Management, LLC 1.05M sh · $34.17M · Q2 2026
- Vivo Capital, LLC 800.00K sh · $25.96M · Q2 2026
- Nan Fung Group Holdings Ltd 630.66K sh · $20.47M · Q2 2026
- Logos Global Management LP 585.00K sh · $18.99M · Q2 2026
- GREAT POINT PARTNERS LLC 317.22K sh · $10.30M · Q2 2026
- HighVista Strategies LLC 211.51K sh · $6.86M · Q2 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held LBRX?
Caligan Partners LP has disclosed LBRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Caligan Partners LP's current position in LBRX?
As of Q2 2026, Caligan Partners LP holds 1.44M shares of LBRX (LB PHARMACEUTICALS INC), valued at $46.67M, representing 2.73% of its reported portfolio and ranking #9.
Has Caligan Partners LP been buying or selling LBRX?
In the latest 13F filing (Q2 2026), Caligan Partners LP held unchanged its position in LBRX. The position peaked in Q2 2026 at 1.44M shares.
Which other funds hold LBRX?
Other major institutional holders of LBRX include Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., Trails Edge Capital Partners, LP, among 110 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.